These findings are consistent with previously published data from three studies of acute intestinal infection in children. 8–10 Diarrhoea resolved more rapidly in patients treated with Enterosgel compared with standard care 8 or antibiotic and standard care. 9 In a randomised prospective open comparative study of the intestinal adsorbents, Enterosgel, Diosmectite and Kaolin, there were no statistically significant differences between the groups for the duration of diarrhoea. Other studies have shown that Enterosgel use in newborns with rotavirus infection can reduce the duration of diarrhoea by 1.4 times, 11 and in antibiotic-associated diarrhoea in adults, result in a decrease in length of hospital stay. 12 This study aims to recruit 430 adult participants with IBS-D, from approximately 30 medical practices and outpatient clinics in the UK. The goal is to investigate whether Enterosgel® can improve IBS-D symptoms, including diarrhoea and abdominal pain, and is well-tolerated. The study will also investigate the impact of Enterosgel® on the quality of life, work productivity and activity and general health, and evaluate whether Enterosgel® has long-term effects. The study will involve four visits and one phone call over 26 weeks. During the study, the participants will complete questionnaires related to IBS and general health, and a daily study diary over 18 weeks. In the first treatment phase, half of the patients will receive Enterosgel® and half will receive a placebo for 8 weeks. In the second treatment phase, all patients will receive Enterosgel® for 8 weeks. Enterosgel is an oral adsorbent, typical of several materials, such as charcoal, clay, silica-based materials and dietary fibres used to treat poisoning and different diseases, such as diarrhoea. 15 The therapeutic mode of action of Enterosgel may occur through the adsorption of bacterial toxins known causes of diarrhoea followed by complete removal from the body. In-vitro studies have demonstrated Enterosgel’s capacity for Escherichia coli endotoxin, bacterial enterotoxins Clostridium difficile toxin A and B, and Shigella toxin 16 and staphylococcal enterotoxins A and B. 17 Other mechanisms may include creation of an adverse environment for pathogenic microorganisms, 18 immunocorrection 19 and inhibiting viral replication, 20 primarily through physical adsorption. A possible benefit of Enterosgel use is in reducing the level of complications of diarrhoea-related bacterial infection. Prospective studies have shown that up to 36% of intestinal infections can be followed by prolonged post-infective irritable bowel syndrome. 21 Thus, treatment with Enterosgel could offer a reduction in secondary care admissions, and financial burden on the health service. However, a large-scale study is recommended with health economics evaluation before introducing Enterosgel onto the UK’s drug tariff.

Enterosgel | Official Website | Drug-Free IBS Reviews – Enterosgel | Official Website | Drug-Free IBS

Enterosgel can be taken in the longer term. Enterosgel can be taken for 21 days continuously followed by a short break for 1-2 days. WHO and Unicef claim that there are approximately two billion cases of diarrhoeal disease every year worldwide, and in children under 5 years of age, 1.9 million die from diarrhoea each year, most often in developing countries. Annually, in the UK, there are 17 million cases and 1 million physician consultations attributed to acute infectious diarrhoea. 1The study tested the adsorption of bacterial toxins released from Clostridium difficile, Shigella and E.coli, which can cause inflammation and damage to the mucosal cells lining the colon resulting in diarrhoea. Stop the treatment with Enterosgel if you do not have bowel movement for 1–2 days, increase intake of water and continue the treatment after the next bowel movement.

IBS trial discovers all-in-one treatment | Latest press

There were no statistically significant differences between groups for secondary outcomes, that is, the duration of diarrhoea defined as the time until the last liquid stool, percentage of patients with diarrhoea resolved from 12 hours to day 3, stool frequency or duration of nausea, vomiting, fever or abdominal pain. However, there was a trend towards shorter duration in the resolution of diarrhoea in the Enterosgel group (25.3 hours vs 38.4 hours), although this was not statistically significant (p=0.20), possibly due to being underpowered.

My only criticism is the timings around taking it, 2 hours before or after meals is difficult and i have to plan meals around this. I’m having to wake up at 6:30am to take this so I can have breakfast a decent time and then I can take my third dosage around 3pm to be able to have dinner at decent time and go out after. Enterosgel has really helped with my IBS diarrhoea. I have been feeling much much better. My symptoms occur less often and are easier to cope with now. Enterosgel should be stored at room temperature (4-30°C), away from direct sunlight and sources of heat. Enterosgel treatment significantly reduced the duration of diarrhoea in adults with patient-reported acute diarrhoea, compared with oral rehydration solution alone.

Virtual trial discovers all-in-one treatment for patients

This was a pragmatic study with flexible treatment instructions in an incremental dosing pattern, to allow participants to find the most appropriate dose to treat their symptoms. Such flexibility hindered our ability to find a set dosage scheme for maximal treatment benefit and as median treatment dose was only two doses per day across the study, this may have prevented patients from taking sufficient treatment to be classified as a responder. At the outset we recognised that this may be a limitation, but we wanted to provide as ‘real world’ a scenario as possible where patient treatment adherence varies, and IBS symptoms fluctuate over time.

This study aims to improve treatment available for IBS-D. Thank you to all the patients and investigators that took part or contributed towards the RELIEVE IBS-D study and made this study possible. Since eligibility was assessed according to the current Rome IV criteria, the applicability of our findings to the estimated 50% of patients with IBS not matching the Rome IV criteria, 34 including those with milder pain, is not known. We may, however, have mitigated for these patients by recruiting a proportion of cases directly from the community setting and when we reduced the eligibility abdominal pain score at screening to lower screening failures. For children 1–3 years old it is advisable to consult a doctor prior to use of Enterosgel. For children Enterosgel can be suspended in the bottle feeder.